Animal study: long-term ritalin doesn't impact growth

July 20, 2012
Animal study: long-term ritalin doesn't impact growth
Chronic use of methylphenidate (Ritalin) in young monkeys has no significant effect on growth or the dopamine system, or the likelihood of becoming addicted to cocaine, according to a study published online July 18 in Neuropsychopharmacology.

(HealthDay) -- Chronic use of methylphenidate (Ritalin) in young monkeys has no significant effect on growth or the dopamine system, or the likelihood of becoming addicted to cocaine, according to a study published online July 18 in Neuropsychopharmacology.

Kathryn E. Gill, from the Wake Forest School of Medicine in Winston Salem, N.C., and colleagues treated 16 juvenile male (about 30 months old) daily with placebo or a sustained-release formulation of methylphenidate for a year, followed by a washout period of three to five months. The animals were then given the opportunity to intravenously administer cocaine over several months.

The researchers found that chronic methylphenidate treatment had no effect on weight gain or other measures of growth. Imaging studies showed no difference on the binding availability of D2/D3 receptors and dopamine transporters, although, after washout, D2/D3 receptor availability did not continue to decline at the same rate as controls. Chronic methylphenidate treatment had no effect on the propensity to acquire cocaine, overall response rates, or cocaine intake.

"In an animal model that closely mimics human development, chronic treatment with therapeutic doses of sustained-release methylphenidate did not have a significant influence on the regulation of dopamine transporters or D2/D3 receptors, or on standard measures of growth," Gill and colleagues conclude. "Furthermore, this and subsequent drug washout did not have an impact on vulnerability to ."

One author disclosed to pharmaceutical companies, including UCB Inc., which provided the methylphenidate.

Explore further: Receptor limits the rewarding effects of food and cocaine

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Receptor limits the rewarding effects of food and cocaine

July 12, 2011
(Medical Xpress) -- Researchers have long known that dopamine, a brain chemical that plays important roles in the control of normal movement, and in pleasure, reward and motivation, also plays a central role in substance ...

Recommended for you

Taking probiotics may reduce postnatal depression

October 18, 2017
Researchers from the University of Auckland and Otago have found evidence that a probiotic given in pregnancy can help prevent or treat symptoms of postnatal depression and anxiety.

Before assigning responsibility, our minds simulate alternative outcomes, study shows

October 17, 2017
How do people assign a cause to events they witness? Some philosophers have suggested that people determine responsibility for a particular outcome by imagining what would have happened if a suspected cause had not intervened.

For older adults, volunteering could improve brain function

October 17, 2017
Older adults worried about losing their cognitive functions could consider volunteering as a potential boost, according to a University of Missouri researcher. While volunteering and its associations with physical health ...

Magic mushrooms may 'reset' the brains of depressed patients

October 13, 2017
Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a 'reset' of their brain activity.

Living near a forest keeps your amygdala healthier

October 13, 2017
A study conducted at the Max Planck Institute for Human Development has investigated the relationship between the availability of nature near city dwellers' homes and their brain health. Its findings are relevant for urban ...

Scientists researching drugs that could improve brain function in people with schizophrenia

October 12, 2017
Virginia Commonwealth University researchers are testing if drugs known as HDAC inhibitors improve cognition in patients with schizophrenia who have been treated with the antipsychotic drug clozapine.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.